TICKERNERD
Menu
UTHRUTHRHealthcare · Drug Manufacturers - Specialty & Generic

UTHR Stock Forecast: United Therapeutics Corp. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$542
+0.97% on the day

The 15 Wall Street analysts covering United Therapeutics Corp. hold a median 12-month price target of $685 — +26.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 6 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$23.2B
Ticker Nerd rank
81 / 100
Median analyst target
$685
Analysts covering
15
Revenue$783.3M−1.9% y/y
Operating income$330.8M
Net income$333.0M
Free cash flow$205.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+12.5%
1M
+11.1%
YTD
+11.2%
1Y
+19.5%
From 52W high
−9.2%
From 52W low
+30.4%
$415
$597
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

UTHR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores United Therapeutics Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
81 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Volatility
98
Quality
91
Issuance
87
Momentum
73
Accruals
64
Growth
45
Revisions
38
Size
9

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Revisions (38): Analysts have, on balance, been cutting their forecasts.

Size (9): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

UTHR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on UTHR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$300$400$500$600$700$800Jan 26Apr 26Jul 26Oct 26UTHRHigh $728Median $685Low $321

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
11 Buy3 Hold1 Sell
Low $321Median $685High $728

The green dot is the last close — the median target sits +26.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
1 Oct 2026BTIGUpgradeBuy$728
24 Sept 2026Goldman SachsInitiatesSell$321
6 Aug 2026RBC CapitalMaintainsOutperform$704 → $677
6 Aug 2026RBC CapitalMaintainsOutperform—
23 July 2026JP MorganMaintainsOverweight$685 → $687
23 July 2026JP MorganMaintainsOverweight—
10 July 2026B of A SecuritiesMaintainsNeutral—
10 July 2026B of A SecuritiesMaintainsNeutral$620 → $613
7 July 2026RBC CapitalMaintainsOutperform—
7 July 2026RBC CapitalMaintainsOutperform$701 → $704
7 May 2026RBC CapitalMaintainsOutperform—
7 May 2026Wells FargoUpgradeOverweight—
10 Apr 2026Morgan StanleyMaintainsEqual-Weight—
31 Mar 2026B of A SecuritiesMaintainsNeutral—
31 Mar 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026Wells FargoMaintainsEqual-Weight—
30 Mar 2026TD CowenMaintainsBuy—
23 Mar 2026Wells FargoMaintainsEqual-Weight—
12 Mar 2026Cantor FitzgeraldMaintainsOverweight—
5 Mar 2026UBSMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. UTHR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

UTHR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, United Therapeutics Corp. returned +19.5% against +17.3% for the S&P 500, dividends included.

UTHR vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Jan 26Apr 26Jul 26Oct 26UTHRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

UTHR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−3.6%
Analysts raising
0
Analysts cutting
1
Fundamentals

United Therapeutics Corp. (UTHR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.5×

Cheaper than 38% of US stocks

Price / sales
7.4×

Cheaper than 18% of US stocks

Price / book
3.6×

Cheaper than 27% of US stocks

EV / EBITDA
13.7×

Cheaper than 25% of US stocks

Growth & margins
Revenue growth (YoY)
−1.9%

Higher than 24% of US stocks

Earnings growth (YoY)
7.6%

Higher than 45% of US stocks

Gross margin
87.3%

Higher than 95% of US stocks

Operating margin
42.2%

Higher than 93% of US stocks

Net margin
41.6%

Higher than 95% of US stocks

Returns & dividend
Return on equity
19.3%

Higher than 80% of US stocks

Return on assets
11.6%

Higher than 94% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

United Therapeutics Corp. (UTHR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • United Therapeutics Corp. has a market value of $23.2B and an enterprise value of $20.6B.

  • Revenue in the twelve months to 30 June 2026: $3.2B. The latest quarter shrank 1.9% year on year.

  • Net income over the same four quarters: $1.3B, a 41.6% net margin.

  • Diluted earnings per share, trailing twelve months: $27.95.

  • Free cash flow in the twelve months to 30 June 2026: $1.1B.

  • United Therapeutics Corp. spent $2.6B on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 42.7M.

  • Trailing P/E: 19.5×; forward P/E: 17.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • United Therapeutics Corp. employs 1,400 people — $2.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

UTHR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
UTHRUnited Therapeutics Corp.$23.2B
81
VTRSViatris, Inc.$20.2B
100
ZTSZoetis, Inc.$29.5B
43
NBIXNeurocrine Biosciences, Inc.$14.5B
87
ELANElanco Animal Health, Inc.$11.2B
97
ALKSAlkermes Plc$6.9B
61
HIMSHims & Hers Health, Inc.$6.9B
17

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own United Therapeutics Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest UTHR news & analysis

UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

Zacks Investment Research · 1 Oct 2026positive

United Therapeutics secured a key patent ruling against Liquidia in a dispute over Yutrepia, a decision that could limit Yutrepia's use for PH-ILD and reduce competition for United Therapeutics' Tyvaso products. The company's stock rose nearly 13% following the news, according to Zacks Investment Research.

Why it matters — United Therapeutics watchers would care because the ruling could protect its Tyvaso franchise from competitive pressure from Liquidia's Yutrepia in the PH-ILD market.

This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Benzinga · 1 Oct 2026positive

Benzinga reports that Wall Street analysts changed their outlooks on top names, and among the top five upgrades for Thursday, an analyst turned bullish on United Therapeutics Corp. (UTHR).

Why it matters — UTHR watchers would care because an analyst upgrade reflects a more favorable outlook for the stock from the investment community.

United Therapeutics Won Its Patent War and Liquidia Collapsed

24/7 Wall Street · 1 Oct 2026positive

A single court ruling in the patent dispute over Yutrepia favored United Therapeutics, sending its share price higher while its rival Liquidia struggled. The excerpt notes that the legal battle over Yutrepia's future is far from settled.

Why it matters — The favorable patent ruling strengthens United Therapeutics' competitive position against its rival in the pulmonary hypertension space, though the ongoing litigation still carries uncertainty.

United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia

Benzinga · 1 Oct 2026positive

United Therapeutics Corp. shares rose in Thursday morning trading after a federal court ruled in its favor in patent litigation against competitor Liquidia Corp. The court victory marks a successful outcome in the ongoing patent dispute between the two companies.

Why it matters — A federal court win in patent litigation against Liquidia could help protect United Therapeutics' market position and intellectual property in its product portfolio.

United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?

Zacks Investment Research · 1 Oct 2026neutral

United Therapeutics (UTHR) shares rose 12.6% last session on higher-than-average trading volume. However, the latest trend in earnings estimate revisions may not support further near-term gains for the stock.

Why it matters — UTHR watchers would care because the sharp price jump is contrasted with a softer earnings estimate revision trend that could limit continued upside in the near term.

FAQ

Frequently asked questions about UTHR stock

What is the UTHR stock price forecast for 2026-2027?

The 15 Wall Street analysts covering United Therapeutics Corp. have a median 12-month price target of $685, with estimates ranging from $321 to $728. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is UTHR stock a buy right now?

Of the 15 analysts covering United Therapeutics Corp., 11 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks United Therapeutics Corp. 81 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank UTHR?

As at 6 Oct 2026, United Therapeutics Corp. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will UTHR stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +26.5% from the last close, and Ticker Nerd's factor model ranks United Therapeutics Corp. 81 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the UTHR stock forecast for 2030?

No analyst covering United Therapeutics Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for UTHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $321 to $728 over the next 12 months.

How has UTHR stock performed over the past year?

United Therapeutics Corp. returned +19.5% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does United Therapeutics Corp. do?

United Therapeutics Corp. is a biotechnology company focused on developing and commercializing medicines for patients with serious, chronic, and life-threatening diseases.

What is the latest news on UTHR?

The most recent item we track (Zacks Investment Research, 1 Oct 2026): "UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%". United Therapeutics secured a key patent ruling against Liquidia in a dispute over Yutrepia, a decision that could limit Yutrepia's use for PH-ILD and reduce competition for United Therapeutics' Tyvaso products. The company's stock rose nearly 13% following the news, according to Zacks Investment Research.

Company

About United Therapeutics Corp.

United Therapeutics Corp. is a biotechnology company focused on developing and commercializing medicines for patients with serious, chronic, and life-threatening diseases. Its portfolio centers on therapies for pulmonary arterial hypertension, including inhaled, oral, and injectable treatments built around treprostinil, as well as additional products for selected rare and severe conditions. The company also markets delivery systems and related treatment options that support ongoing care in specialized respiratory and cardiovascular settings. United Therapeutics Corp. serves patients, clinicians, and healthcare providers across the United States and international markets, with a business model centered on specialty pharmaceuticals and disease-specific therapies. Headquartered in Silver Spring, Maryland, United Therapeutics Corp. operates as a biotechnology company with a strong focus on addressing complex unmet medical needs through commercial products and targeted treatment platforms.

CEO Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. · 1,400 employees · United States · https://www.unither.com